Nanjing Legend Biotech Surprises ASCO with Strong CAR-T Results in Multiple Myeloma

China’s Nanjing Legend Biotech surprised attendees at Chicago's ASCO meeting with very positive results in an early trial of its CAR-T treatment for multiple myeloma. Of 35 patients enrolled in the trial, 33 (94%) experienced clinical remission, ranging from a complete to a partial response. All enrollees had relapsed or refractory disease. Of the 19 patients who were observed for at least four mouths, 14 experienced a “stringent” complete response (sCR) and five had partial response. At least five patients have maintained sCR status for over a year. More details.... Share this with colleagues: // //